Benitec Biopharma Inc. Share Price Deutsche Boerse AG
Equities
BJ9
US08205P2092
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.06 EUR | -2.70% | -.--% | -.--% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 108M 71.79M 66.18M 5.64B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.03
x | P/E ratio 2025 * |
-8.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.72% |
1 day | -2.70% |
Managers | Title | Age | Since |
---|---|---|---|
Jerel Banks
CEO | Chief Executive Officer | 49 | 30/09/16 |
Peter Roelvink
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/15 |
Megan Boston
CMP | Compliance Officer | 52 | 31/07/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
J. Buchi
BRD | Director/Board Member | 69 | 31/03/13 |
Edward Smith
BRD | Director/Board Member | 53 | 13/04/20 |
Peter Francis
BRD | Director/Board Member | 68 | 31/01/06 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- BNTC Stock
- BJ9 Stock